Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed
Agency requests Phase III study with MRSA subgroup: cost of additional study could lead company to seek development partner.
Agency requests Phase III study with MRSA subgroup: cost of additional study could lead company to seek development partner.